Oncology Corporate Profile
ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary products that activate the immune system of cancer patients to recognize and eradicate tumors. The Company’s lead product candidate, AM0010 (pegilodecakin), stimulates the survival, expansion and killing (cytotoxic) potential of a particular type of white blood cell in the immune system called CD8+ T cells. CD8+ T cells recognize and kill cancer cells and an increased presence of intra-tumoral CD8+ T cells may result in improved prognosis and survival in patients.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|AM0010||PEG-IL-10||Non Small Cell Lung Cancer (NSCLC)||I|
|AM0010||PEG-IL-10||Renal cell carcinoma (RCC)||I|
|AM0010||PEG-IL-10||Various cancer types||I|
View additional information on product candidates here »